Advertisement

GSK's new triple lung drug beats other modern inhalers in study

GSK's new triple lung drug beats other modern inhalers in study
From Reuters - September 20, 2017

LONDON (Reuters) - GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.

Britains biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair.

Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZenecas long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

Advertisement

Continue reading at Reuters »